Pascual Sanchez-Juan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11564481/publications.pdf

Version: 2024-02-01

77 papers	7,520 citations	136950 32 h-index	69250 77 g-index
85 all docs	85 docs citations	85 times ranked	11070 citing authors

#	Article	IF	Citations
1	Genetic Architecture of Primary Tauopathies. Neuroscience, 2023, 518, 27-37.	2.3	9
2	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
4	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	6.2	5
5	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
6	Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 21-26.	2.2	5
7	The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals. Alzheimer's Research and Therapy, 2022, 14, 57.	6.2	8
8	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
9	Major Surgery Affects Memory in Individuals with Cerebral Amyloid-Î² Pathology. Journal of Alzheimer's Disease, 2021, 79, 863-874.	2.6	9
10	Long runs of homozygosity are associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 142.	4.8	6
11	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
12	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
13	LAMP2 deficiency attenuates the neurodegeneration markers induced by HSV-1 infection. Neurochemistry International, 2021, 146, 105032.	3.8	5
14	Serial DaTâ€SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 yearsâ€™ followâ€up. European Journal of Neurology, 2021, 28, 4204-4208.	3.3	6
15	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimerâ€™s Disease. Cerebral Cortex, 2020, 30, 2083-2098.	2.9	25
16	Very early Guillain-BarrÃ© syndrome: A clinical-electrophysiological and ultrasonographic study. Clinical Neurophysiology Practice, 2020, 5, 1-9.	1.4	17
17	Evaluation of choroidal thickness in prodromal Alzheimerâ€™s disease defined by amyloid PET. PLoS ONE, 2020, 15, e0239484.	2.5	11
18	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42

#	Article	IF	Citations
19	A snake that bites its own tail. Acquisition and loss of concepts in children and semantic dementia patients through the analysis of drawings. Cortex, 2020, 128, 162-173.	2.4	1
20	Physical Activity Is Associated With Better Executive Function in University Students. Frontiers in Human Neuroscience, 2020, 14, 11.	2.0	21
21	Genetic architecture of neurodegenerative dementias. Neuropharmacology, 2020, 168, 108014.	4.1	5
22	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2020, 12, 603790.	3.4	17
23	Cognitive and Behavioral Profiles of Left and Right Semantic Dementia: Differential Diagnosis with Behavioral Variant Frontotemporal Dementia and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 1129-1144.	2.6	16
24	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
25	Characterization of Alzheimerâ€™s Disease Micro-RNA Profile in Exosome-Enriched CSF Samples. Methods in Molecular Biology, 2019, 2044, 343-352.	0.9	3
26	A Brief Drawing Task for the Differential Diagnosis of Semantic Dementia. Journal of Alzheimer's Disease, 2019, 72, 151-160.	2.6	7
27	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
28	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
29	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2019, 68, 1535-1547.	2.6	11
30	A unicenter, prospective study of Guillainâ€BarrÃ© syndrome in Spain. Acta Neurologica Scandinavica, 2019, 139, 546-554.	2.1	6
31	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
32	The MAPT H1 Haplotype Is a Risk Factor for Alzheimerâ€™s Disease in APOE Îµ4 Non-carriers. Frontiers in Aging Neuroscience, 2019, 11, 327.	3.4	27
33	A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET/CT. Nuclear Medicine Communications, 2019, 40, 525-531.	1.1	5
34	Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 570-578.	3.7	31
35	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Neurobiology of Aging, 2018, 64, 58-67.	3.1	8
36	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58

#	Article	IF	Citations
37	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
38	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
39	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
40	Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. Journal of Alzheimer's Disease, 2018, 63, 1025-1033.	2.6	5
41	MicroRNA Profile in Patients with Alzheimerâ€™s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. Journal of Alzheimer's Disease, 2017, 57, 483-491.	2.6	126
42	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
43	Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease. Neurology, 2017, 89, 439-444.	1.1	41
44	The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics. PLoS ONE, 2017, 12, e0178093.	2.5	5
45	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting. Clinical Nuclear Medicine, 2016, 41, e18-e23.	1.3	22
46	Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients. Nuclear Medicine Communications, 2016, 37, 1189-1196.	1.1	7
47	Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019Sâ€“associated Parkinson's disease. Neurobiology of Aging, 2016, 38, 214.e1-214.e5.	3.1	31
48	Binge Drinking in Young University Students Is Associated with Alterations in Executive Functions Related to Their Starting Age. PLoS ONE, 2016, 11, e0166834.	2.5	35
49	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
50	A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk. PLoS ONE, 2015, 10, e0123654.	2.5	28
51	Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. Neurobiology of Aging, 2015, 36, 1105-1109.	3.1	31
52	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.1	131
53	Spinal nerve involvement in early Guillainâ€“BarrÃ© syndrome: A clinico-electrophysiological, ultrasonographic and pathological study. Clinical Neurophysiology, 2015, 126, 810-819.	1.5	62
54	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	3.1	75

#	Article	IF	Citations
55	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
56	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
57	Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology, 2014, 82, 230-238.	1.1	74
58	Nerve ultrasonography in early Guillainâ€BarrÃ© syndrome: a need for large prospective studies. Journal of the Peripheral Nervous System, 2014, 19, 344-344.	3.1	3
59	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	3.1	92
60	Serum uric acid and risk of dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 637-639.	2.2	23
61	The sex-specific associations of the aromatase gene with Alzheimerâ€™s disease and its interaction with IL10 in the Epistasis Project. European Journal of Human Genetics, 2014, 22, 216-220.	2.8	35
62	Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology, 2013, 80, 621-626.	1.1	81
63	Neurodegenerative Disease Phenotypes in Carriers of MAPT p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 302-309.	1.3	40
64	Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Movement Disorders, 2013, 28, 1737-1740.	3.9	39
65	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldtâ€“Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
66	Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiology of Aging, 2012, 33, 1487.e21-1487.e28.	3.1	40
67	Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimerâ€™s disease. Journal of Neurology, 2011, 258, 1538-1539.	3.6	11
68	A polymorphism in the regulatory region of PRNPis associated with increased risk of sporadic Creutzfeldt-Jakob disease. BMC Medical Genetics, 2011, 12, 73.	2.1	18
69	High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain). Movement Disorders, 2011, 26, 2343-2346.	3.9	40
70	Caspase-1 genetic variation is not associated with Alzheimer's disease risk. BMC Medical Genetics, 2010, 11, 32.	2.1	8
71	Epistasis Between Intracellular Cholesterol Trafficking-Related Genes (NPC1 and ABCA1) and Alzheimer's Disease Risk. Journal of Alzheimer's Disease, 2010, 21, 619-625.	2.6	21
72	Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Research, 2009, 1280, 166-171.	2.2	38

#	Article	IF	Citations
73	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. Journal of Neurology, 2009, 256, 1620-1628.	3.6	77
74	Age-dependent association of KIBRA genetic variation and Alzheimer's disease risk. Neurobiology of Aging, 2009, 30, 322-324.	3.1	69
75	Source of Variant Creutzfeldt-Jakob Disease outside United Kingdom. Emerging Infectious Diseases, 2007, 13, 1166-1169.	4.3	29
76	Association of genetic variants of ABCA1 with Alzheimer's disease risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 964-968.	1.7	42
77	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. Journal of Neurology, 2007, 254, 901-906.	3.6	72